The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called "target oriented therapies".
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopha.2006.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.
Oncotarget
January 2013
Department of Investigational Cancer Therapeutics.
Purpose: Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we systematically analyzed the characteristics and outcomes for GC and CC patients treated on phase I trials with an emphasis on targeted agents and locoregional therapies.
Results: Of 40 treated patients (GC=6; CC=34; median age, 60 years), 8 (20%) had stable disease (SD) > 6 months, 3 (8%) partial response (PR), on protocols with hepatic arterial drug infusion and anti-angiogenic, anti-HER-2/neu or novel MAPK/ERK kinase (MEK) inhibitors.
Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Curr Cancer Drug Targets
March 2009
Medical Oncology & Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, Brussels, Belgium.
Overexpression of the human epidermal growth factor receptor 2 (HER-2) represents a biological subclass of breast cancer with distinct molecular alterations, clinical behavior, and response to systemic therapy. Trastuzumab is a monoclonal antibody directed against HER-2 which has revolutionized the management of both early and advanced breast cancer. It may exert its anti-cancer effects through inhibition of intracellular signaling, upregulation of p27, impaired angiogenesis, induction of immune-mediated destruction, and blockade of cleavage of the extracellular domain of HER-2.
View Article and Find Full Text PDFPresent treatment and future expectations in advanced pancreatic cancer.
Anticancer Res
June 2008
First Department of Oncology, Errikos Dunant Hospital, Athens, Greece.
Advanced or metastatic pancreatic cancer is an incurable disease. The main treatment is chemotherapy with cytotoxic agents. On the basis of our experience in clinical trials, the objectives have been to determine response rate, life prolongation and clinical benefit.
View Article and Find Full Text PDFAnti-angiogenic and anti-HER therapy.
Biomed Pharmacother
July 2006
Division of Medical Oncology, San Filippo Neri Hospital, Via Martinotti 20, 00135 Rome, Italy.
The recent completion of the human genome sequence provided the basis and the tools to better understand the cellular biological complexity in both healthy and disease conditions, such as human cancer. In recent years, the improvement in biological and molecular knowledge enabled us to identify new targets and innovative drugs, allowing the beginning of new therapeutic strategies based on the so called "target oriented therapies".
View Article and Find Full Text PDF[Molecular-targeted agents in breast cancer].
Gan To Kagaku Ryoho
June 2006
Dept. of Breast and Endocrine Surgery, Tokai University School of Medicine.
Recently, molecular-biological analyses of the mechanisms of cancer development have created new anticancer agents, molecular-targeted agents. Among them, the humanized anti-HER 2 monoclonal antibody, trastuzumab (Herceptin), has been available for clinical use in metastatic breast cancer in Japan since June, 2001. Now, it has become one of the key drugs for metastatic breast cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!